Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases
Conditions
Brief summary
The primary endpoint is the 2-year metastases progression free survival
Detailed description
3 years PSA progression., Start of 2nd line treatment., Start 2nd MDRT treatment for new (progressive) oligometastases., Acute and late toxicity (late toxicity up to 3 years)., Clinical progression-free survival., Quality of life., Progression pattern., Time to start of palliative ADT., Time to castration-resistance., Disease-specific and overall survival., Sensitivity of the imaging modality (PSMA-PET/CT or PSMA-PET/MRI) for patients receiving MDRT., Predictive biomarkers.
Interventions
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the 2-year metastases progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 3 years PSA progression., Start of 2nd line treatment., Start 2nd MDRT treatment for new (progressive) oligometastases., Acute and late toxicity (late toxicity up to 3 years)., Clinical progression-free survival., Quality of life., Progression pattern., Time to start of palliative ADT., Time to castration-resistance., Disease-specific and overall survival., Sensitivity of the imaging modality (PSMA-PET/CT or PSMA-PET/MRI) for patients receiving MDRT., Predictive biomarkers. | — |
Countries
Netherlands
Outcome results
None listed